Summary
Johnson & Johnson reported strong financial performance for the second quarter and first six months of 2004, demonstrating significant sales growth across all its business segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Worldwide sales increased by 11.1% for the quarter and 14.3% for the six-month period compared to the prior year, with international sales showing particularly robust growth, partly due to favorable currency exchange rates. The company's profitability also saw a substantial improvement, with net earnings rising significantly year-over-year. This was driven by operational growth, effective cost management, and a lower effective tax rate, partly due to the absence of significant non-deductible in-process research and development (IPR&D) charges that impacted the prior year's comparable period. The company also continued its commitment to returning value to shareholders, evidenced by a 42nd consecutive year of dividend increases. While the company faces ongoing litigation and regulatory scrutiny, particularly concerning product liability and patent disputes, management expressed confidence in its ability to manage these risks. The overall financial health and growth trajectory presented in this filing suggest a positive outlook for investors, underscoring the company's diversified business model and effective execution of its strategies.
Key Highlights
- 1Worldwide sales increased by 11.1% to $11.48 billion for the second quarter of 2004 and by 14.3% to $23.04 billion for the first six months of 2004 compared to the prior year.
- 2Net earnings for the second quarter of 2004 more than doubled to $2.46 billion ($0.82 per diluted share) from $1.21 billion ($0.40 per diluted share) in the prior year's quarter.
- 3For the first six months of 2004, net earnings increased to $4.95 billion ($1.65 per diluted share) from $3.28 billion ($1.09 per diluted share) in the comparable period of 2003.
- 4All three business segments – Consumer, Pharmaceutical, and Medical Devices and Diagnostics – reported significant sales growth, with Medical Devices and Diagnostics showing the strongest percentage increase (17.1% for six months).
- 5The company increased its regular cash dividend by 18.8% to $0.285 per share, marking the 42nd consecutive year of dividend increases.
- 6Cash flow from operations increased by $1.1 billion to $4.78 billion for the first six months of 2004, reflecting improved profitability and working capital management.
- 7The effective income tax rate for the first six months of 2004 decreased to 28.6% from 34.2% in the prior year, largely due to the absence of non-deductible IPR&D charges.